Circadian Therapeutics to Attend JP Morgan Healthcare Conference Circadian Therapeutics to attend JP Morgan Healthcare Conference in San Francisco Dr Mark Sampson, CEO will be attending the JP Morgan Healthcare Conference in person from 9th -12th January 2022....
CT1500 Phase 1 Study CT1500 Phase 1 Study Circadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marks move to a clinical stage company • First subject dosed for Phase I study• CT-1500 being developed to treat Non-24 Sleep-Wake...
